Yesafili Injection, Solution
NDC Package 83257-013-01

11-digit billing NDC: 83257001301
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Yesafili (aflibercept-jbvf) injection is yESAFILI is indicated for the treatment of:. This formulation utilizes a injection, solution delivery system. Marketed by Biocon Biologics Inc., this product is identified by NDC 83257-013 and is authorized under FDA application BLA761274.

Identification & Billing

NDC Package Code
83257-013-01
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / .05 mL in 1 VIAL, SINGLE-DOSE
Product Code
83257-013
11-Digit Billing Format
83257001301

Clinical Specifications

Proprietary Name
Yesafili
Non-Proprietary Name
Aflibercept-jbvf
Substance Name
Aflibercept
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravitreal - Administration within the vitreous body of the eye.
Active Ingredient(s)
AFLIBERCEPT 2 mg/.05mL
Pharmacologic Class
Usage Information
YESAFILI is indicated for the treatment of:

Regulatory & Marketing

Labeler Name
Biocon Biologics Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761274
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
11-03-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83257-013-01 identifies a specific commercial package of 1 vial, single-dose in 1 carton / .05 ml in 1 vial, single-dose of Yesafili, a human prescription drug labeled by Biocon Biologics Inc.. This injection, solution is formulated for intravitreal use and contains aflibercept as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Biocon Biologics Inc. on November 03, 2026. The current certification is valid through December 31, 2027.

How is this Biocon Biologics Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83257001301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83257-013-01
11-Digit CMS (5-4-2)
83257-0013-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.